S&P 500 Healthcare Sector SEC Filings — March 09, 2026

09-03-2026

Signet Jewelers announced preliminary Q4 FY26 sales of $2.34-2.35B with SSS declining 0.7-0.9% YoY despite AUR up 4-5% and sequential monthly improvements, while full year FY26 sales reached ~$6.8B with SSS up 1.2-1.3% YoY and AUR up 6-7%. Operating income is projected at $313-318M for Q4 (adjusted $322-327M) and $388-393M for FY26 (adjusted $510-515M), with expected free cash flow exceeding $500M amid a modest gross merchandise margin decline from broader promotions. Sales momentum continued positively into Valentine's Day and March, supported by the Grow Brand Love strategy across Kay, Zales, and Jared.

• ·Asset impairments: $7M in Q4 FY26, $91M in FY26 (primarily goodwill and indefinite-lived intangible assets).
• ·Restructuring and related charges: $27M in FY26 (Grow Brand Love strategy).
• ·Loss on divestitures: $2M in Q4 FY26, $4M in FY26 (UK prestige watch business).
• ·Operates ~2,600 stores.
• ·Investor conferences: Citi March 9, BofA March 10, UBS March 11, 2026; presentation webcast March 9 at 4:15 PM ET.
• ·FY27 guidance and strategic priorities to be provided March 16, 2026 (next Thursday).

09-03-2026

Editas Medicine reported a significantly narrowed Q4 2025 net loss of $5.6M ($0.06/share) from $45.4M ($0.55/share) in Q4 2024 and full-year 2025 net loss of $160.1M ($1.80/share) from $237.1M ($2.88/share), driven by sharp R&D expense cuts to $27.4M (Q4) and $90.0M (FY) following reni-cel discontinuation; however, Q4 collaboration revenues declined 19% to $24.7M from $30.6M, cash dropped 46% to $146.6M from $269.9M, and FY restructuring charges rose to $60.7M from $12.2M. The company advanced lead candidate EDIT-401, showing >90% mean LDL-C reduction in preclinical studies, with IND/CTA submission on track for mid-2026 and first-in-human HeFH trial data by year-end 2026, supported by cash runway into Q3 2027.

• ·Preparing to present additional preclinical data for EDIT-401 by mid-2026.
• ·Plans to participate in Barclays 28th Annual Global Healthcare Conference on March 12, 2026.
• ·R&D expenses Q4 decreased $21.2M YoY primarily due to reni-cel discontinuation.
• ·G&A expenses decreased $5.0M YoY in Q4 and $22.1M in FY due to workforce reduction.

09-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 9, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'The Top 20 Things You Probably Did Not Know About AITX and RAD', attached as Exhibit 99.1. The information is furnished and explicitly stated as not material or filed for liability purposes under the Exchange Act.

09-03-2026

This Rule 425 filing from Nuveen Municipal High Income Opportunity Fund (NMZ) urges shareholders of Nuveen New Jersey Quality Municipal Income Fund to vote 'FOR' all proposals by March 19, 2026, with less than 3 days remaining as of the March 9, 2026 filing date. The Board strongly recommends approval, stating it is in the best interest of the Fund, and emphasizes that every vote counts to achieve sufficient participation. Proxy solicitation support is available via toll-free number from Computershare.

• ·Commission File No. for NMZ: 333-290590
• ·Commission File No. for Nuveen New Jersey Quality Municipal Income Fund: 811-09455
• ·Voting support hours: 9:00 am to 11:00 pm Eastern Time weekdays; Noon to 6:00 pm Eastern Time Saturday
• ·Contact address: 51 West 52nd Street, 6th Floor, New York, NY 10019

09-03-2026

Tri-County Financial Group, Inc. reported total assets of $1.6B, up 3.7% YoY, with loans growing 3.0% to $1.3B and net income surging 31.0% to $13.7M driven by 16.8% higher net interest income and 10.2% noninterest income growth. However, nonperforming loans ratio rose to 0.43% from 0.33%, credit loss expense flipped to $0.7M from a $1.3M recovery, and allowance coverage of nonperforming loans declined to 264.9% from 346.9%. Financial ratios improved with ROA at 0.88% (up from 0.68%) and ROE at 9.09% (up from 7.45%), but noninterest expense increased 4.9%.

• ·Return on average assets improved to 0.88% from 0.68%; Return on average equity to 9.09% from 7.45%.
• ·Net interest margin expanded to 3.40% from 2.96%.
• ·Tier 1 leverage capital ratio of subsidiary Bank at 10.51% (up from 10.30%); Risk-based total capital ratio at 14.91% (up from 14.50%).
• ·Mortgage banking income up 13.4% to $11.3M; Insurance services up 24.6%.

09-03-2026

News Corporation disclosed via 8-K information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The disclosures, dated as noted in Exhibits 99.1 and 99.2, include forward-looking statements on potential repurchases subject to market conditions and regulations. No specific repurchase volumes or amounts were detailed in the filing.

• ·Date of earliest event reported: March 6, 2026
• ·Filing signed and dated: March 9, 2026

09-03-2026

Jefferies Financial Group Inc. filed a Form 8-K on March 9, 2026, reporting an event dated October 8, 2025, under Item 7.01 Regulation FD Disclosure, announcing the issuance of a press release attached as Exhibit 99.1. The filing includes standard registrant details and lists of registered securities but provides no financial metrics, performance data, or period comparisons.

• ·Date of earliest event reported: October 8, 2025
• ·Registrant address: 520 Madison Ave., New York, New York 10022
• ·Telephone number: 212-284-2300
• ·Commission File Number: 001-05721
• ·IRS Employer Identification No.: 13-2615557

09-03-2026

Spruce Biosciences reported FY2025 financial results with total operating expenses of $36.5M (down 40% YoY from $61.1M) and net loss of $39.0M (improved 26% from $53.0M YoY), driven by lower R&D spending after ceasing tildacerfont development, though G&A rose 16% YoY to $17.0M and collaboration revenue fell to $0 from $4.9M. Cash stood at $48.9M as of Dec 31, 2025, funding operations into early 2027, bolstered by a January 2026 $50M loan facility from Avenue Capital (initial $15M tranche). Key updates include positive FDA Type B meetings supporting Q4 2026 BLA for TA-ERT in MPS IIIB, appointment of Dale Hooks as CCO, and other leadership additions.

• ·Stock-based compensation expenses: $2.6M in FY2025 (down from $5.3M in FY2024)
• ·Net loss per share: $(50.83) in FY2025 vs $(96.40) in FY2024
• ·Weighted-average shares outstanding: 766,598 in FY2025 (up from 550,146 in FY2024)
• ·PRV program reauthorized through September 30, 2029; TA-ERT eligible if approved

09-03-2026

Protagenic Therapeutics, Inc. reported total assets of $4.4M as of Dec 31, 2025, up significantly from $89K at Mar 31, 2025, driven by the acquisition of Phytanix Bio which added $943K cash and $2.1M intangibles; cash increased to $2.2M. However, operating expenses rose 130% YoY to $925K in Q3 FY26, resulting in a $925K operating loss, while 9M net loss widened 112% YoY to $3.7M despite a Q3 net income of $2.2M from $3.1M derivative gain. Cash used in operations was $3.1M over 9M, offset by $4.4M financing inflows.

• ·Notes payable increased to $3.16M from $1.67M.
• ·Accounts payable rose to $2.03M from $961K.
• ·Derivative liabilities decreased to $544K from $1.38M.
• ·Weighted average shares basic/diluted Q3: 1,934,878 vs 5,395,604 YoY.
• ·Reverse merger accounted under ASC 805 with purchase price allocation of $2.34M.

09-03-2026

Occidental Petroleum (OXY) announced early tender results for its cash tender offers and consent solicitations on several senior notes and debentures, increasing the Aggregate Cap from $700M to $1.2B and fully accepting $21.5M of 0% 2036 Notes and $843.3M of 6.125% 2031 Notes, while prorating acceptance of $335.2M (28.7%) of 6.625% 2030 Notes due to oversubscription. No tenders were accepted for the 7.200% 2029 or 7.950% 2029 Debentures. Requisite consents were obtained only for the 6.125% 2031 Notes amendments, with early settlement on March 9, 2026.

• ·Early Tender Time: 5:00 p.m. NYT on March 4, 2026
• ·Early Settlement Date: March 9, 2026
• ·Tender Offers Expiration Date: March 19, 2026 (unless extended)
• ·Offer to Purchase dated February 19, 2026
• ·Early Tender Premium: $30 per $1,000 principal for accepted notes
• ·Requisite consents not obtained for 6.625% 2030 Notes, 7.200% 2029 Debentures, or 7.950% 2029 Debentures
• ·Accreted value for 0.000% 2036 Notes as of April 10, 2026: approximately $580,925.31 per $1M principal at maturity

09-03-2026

Precision Drilling Corporation filed its Form 40-F annual report for the fiscal year ended December 31, 2025, on March 9, 2026, including audited annual financial statements under IFRS and an Annual Information Form. The company reported 12,932,399 common shares outstanding as of December 31, 2025, with shares traded on the NYSE under PDS. No specific financial performance metrics, period-over-period changes, or material positive/negative variances were detailed in the provided filing content.

• ·Auditor: KPMG LLP (Calgary, Alberta, Canada)
• ·Principal executive offices: 800, 525 - 8 Avenue, S.W., Calgary, Alberta, Canada T2P 1G1
• ·Agent for service in US: Precision Drilling (US) Corporation, Houston, Texas
• ·Incorporated in Alberta, Canada; Primary SIC: 1381
• ·References segments: Contract Drilling Services, Completion and Production Services, International, Corporate and Other
• ·Currencies referenced: CAD, USD

09-03-2026

Anixa Biosciences reported no revenue for the three months ended January 31, 2026, with net loss attributable to common shareholders narrowing 19% YoY to $2.6M from $3.2M, driven by R&D expenses down 29% and G&A down 12%, while interest income declined to $131k. Total assets decreased 5% QoQ to $15.2M as of January 31, 2026 from $16.1M, due to lower short-term investments (-9%), though cash rose 24% to $1.5M and the company raised $1.6M net via at-the-market equity offering. Cash used in operations improved to $2.6M from $2.9M YoY, but net cash from investing activities fell sharply to $1.2M from $2.7M.

• ·Revenue remained at $0 for both periods.
• ·Weighted average common shares outstanding increased to 33.24M from 32.20M YoY.
• ·Basic and diluted EPS improved to ($0.08) from ($0.10) YoY.
• ·Noncontrolling interest loss of $20k in Q1 FY2026.
• ·Stock-based compensation in R&D: $338k (down from $397k YoY); in G&A: $458k (down from $658k YoY).

09-03-2026

Abbott Laboratories filed an 8-K announcing entry into a material agreement for the issuance of multiple series of senior notes, including Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.300% Notes due 2033, 4.650% Notes due 2036, 4.750% Notes due 2038, 5.500% Notes due 2056, and 5.600% Notes due 2066, creating a direct financial obligation under Items 1.01 and 2.03. Forward-looking statements reference a proposed acquisition of Exact Sciences and the expected use of proceeds from the notes offering, subject to risks and uncertainties. No principal amounts, pricing details, or performance metrics were disclosed.

• ·Filing date: March 09, 2026
• ·Legal opinion provided by Wachtell, Lipton, Rosen & Katz
• ·References risks in Abbott’s Form 10-K for year ended December 31, 2025

09-03-2026

Humana Inc. priced a $1.0 billion public offering of fixed-to-fixed rate junior subordinated notes due 2056 at 100.000% of principal amount, expected to close on March 9, 2026. Net proceeds of approximately $986 million will be used for general corporate purposes, including repayment of existing indebtedness such as commercial paper borrowings. The offering is led by joint book-running managers including Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc., and Wells Fargo Securities, LLC.

• ·Announcement date: March 5, 2026
• ·Offered pursuant to effective shelf registration statement with SEC
• ·Risk disclosure: Medicare Advantage Star Ratings significantly declined in 2025; ongoing lawsuit against 2025 ratings decision appealed October 14, 2025, potentially impacting 2026 quality bonus payments

09-03-2026

First Business Financial Services, Inc. (FBIZ) filed Supplement No. 1 to its Proxy Statement dated March 5, 2026, solely to add voting details for Item 2: Approval of the 2026 Equity Incentive Plan ahead of the Annual Meeting on April 24, 2026. The proposal requires the affirmative vote of a majority of votes cast (assuming quorum), is classified as non-routine (no broker discretion), and abstentions/broker non-votes have no effect on the outcome.

• ·Supplement filed with SEC on March 9, 2026
• ·Does not revise or update any other Proxy Statement information

09-03-2026

UnitedHealth Group Incorporated announced that senior leaders will participate in an interview format session at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, beginning at 11:30 a.m. Eastern Time, discussing the company’s strategy, market positions, recent results, and expectations for its end markets. A live audio webcast of the presentation will be available through the Investor Relations page of the company’s website at www.unitedhealthgroup.com.

• ·Filing date: March 9, 2026
• ·Website for webcast: www.unitedhealthgroup.com

09-03-2026

GCI Liberty, Inc. announced on March 6, 2026, via Regulation FD Disclosure, that its virtual Annual Meeting of Stockholders will be held on Monday, May 11, 2026, at 11:30 a.m. MT. A press release detailing the announcement is attached as Exhibit 99.1.

• ·Securities registered: Series A GCI Group Common Stock (GLIBA) and Series C GCI Group Common Stock (GLIBK) on The Nasdaq Stock Market LLC
• ·Registrant is an emerging growth company

09-03-2026

CACI International Inc completed its all-cash acquisition of ARKA Group L.P. for $2.6B on March 9, 2026, adding industry-leading electro-optical/infrared (EO/IR) and hyperspectral imaging capabilities, plus Agentic AI-based software for geospatial intelligence to bolster national security missions. The deal integrates 1,100 ARKA employees into CACI's 27,000-employee workforce, expanding its space-based sensors portfolio and market position. No financial performance declines or flat metrics were reported in connection with the acquisition.

• ·CACI acquired ARKA from funds managed by Blackstone Tactical Opportunities.
• ·Wells Fargo served as CACI's exclusive financial advisor and provided committed financing.
• ·CACI referenced as Fortune World's Most Admired Company, Fortune 500, Russell 1000 Index, and S&P MidCap 400 Index member.
• ·Forward-looking statements subject to risks in CACI’s Form 10-K for fiscal year ended June 30, 2025.

09-03-2026

Catheter Precision, Inc. adopted a Certificate of Designation for Series [C][D] Convertible Preferred Stock, authorizing issuance of up to an unspecified number of shares pursuant to a Purchase Agreement, with terms including conversion rights and protective covenants. These covenants restrict the Company from incurring new indebtedness (other than Permitted Indebtedness), liens, paying dividends, or engaging in acquisitions, mergers, or asset sales exceeding 10% of assets without Required Holders' consent, applicable while 33.33% of issued shares remain outstanding. Currently, 2,229 preferred shares are issued and outstanding out of 10,000,000 authorized.

• ·Covenants prohibit amendments to charter documents materially adverse to holders (except specific quorum or designation amendments).
• ·Company restricted from Change of Control transactions without consent.
• ·Acquisition limit: no transactions for >10% of total consolidated assets.

09-03-2026

Apollo Commercial Real Estate Finance, Inc. (ARI) is seeking stockholder approval via proxy for the sale of its entire commercial real estate loan portfolio (excluding two loans totaling $146M principal as of Dec 31, 2025) to Athene at 99.7% of commitment amounts, expected to generate ~$1.4B net cash and ~$1.7B common stockholders’ equity ($12.05/share) after debt repayment and expenses, while retaining $464.3M in real estate owned positions. ARI plans to deploy proceeds into a refreshed investment strategy, has declared a $0.25/share Q1 2026 dividend targeting ~8% annualized yield on post-closing BVPS, with closing anticipated in Q2 2026. However, failure to approve could require a $50M termination fee to Athene, and other risks are noted.

• ·Purchase Agreement entered into on January 27, 2026
• ·Closing conditions include stockholder approval, no legal restraints, and entry into A&R Management Agreement
• ·Proxy statement filed March 09, 2026; Special Meeting details referenced but not specified here
• ·No appraisal rights for stockholders; Asset Sale taxable to ARI but not expected to trigger stockholder taxes
• ·Base management fees under A&R Management Agreement payable in shares (with cash exceptions); incentive fees eligible post-ROE Milestone

09-03-2026

On March 9, 2026, Ellington Financial Inc. announced quarterly and monthly dividend declarations via press release: $0.13 per share for common stock (monthly), $0.390625 per share for 6.250% Series B Preferred Stock (quarterly), $0.5390625 per share for 8.625% Series C Preferred Stock (quarterly), and $0.4375 per share for 7.00% Series D Preferred Stock (quarterly). These dividends reflect stable payout commitments to shareholders across share classes with no changes or reductions indicated.

• ·Common stock dividend payable April 30, 2026 to record date March 31, 2026.
• ·Series B and Series C preferred dividends payable April 30, 2026 to record date March 31, 2026.
• ·Series D preferred dividend payable March 30, 2026 to record date March 20, 2026.

09-03-2026

MBX Biosciences announced a successful End-of-Phase 2 meeting with the FDA and plans to initiate a Phase 3 double-blind placebo-controlled trial for once-weekly canvuparatide in treating chronic hypoparathyroidism in Q3 2026, enrolling approximately 160 patients in a 3:1 randomization. The trial includes a four-week fixed dose period of 600 ug canvuparatide (or placebo), an eighteen-week dose-titration period, and a four-week maintenance period, with the primary endpoint at week 26 assessing proportion of participants achieving normal serum calcium and independence from conventional therapy. Canvuparatide has also been granted Orphan Drug Designation by the European Medicines Agency for chronic hypoparathyroidism.

• ·Phase 3 trial structure: 4-week fixed dose (600 ug canvuparatide or placebo), 18-week dose-titration, 4-week maintenance; primary endpoint at week 26 followed by open-label extension
• ·Secondary endpoints include normalization of urinary calcium
• ·Orphan Drug Designation by EMA supports European clinical development

09-03-2026

Circle Internet Group, Inc. (CRCL) reported robust growth in its core stablecoin business, with USDC in circulation surging 72% YoY to $75.3B at December 31, 2025 (from $43.9B), driving total revenue and reserve income up 63.9% YoY to $2.75B. However, the company posted a net loss of $70M in 2025 versus a $157M profit in 2024, due to operating expenses ballooning 139.9% YoY to $1.18B (led by compensation expenses +220.7%), resulting in an operating loss and RLDC margin remaining flat at 39%. Adjusted EBITDA rose strongly to $582M (54% margin) from $285M (43% margin), highlighting non-GAAP operational strength amid GAAP challenges.

• ·Net cash provided by operating activities increased to $542M in 2025 from $345M in 2024.
• ·Net cash provided by financing activities rose to $31.9B in 2025 from $19.5B in 2024, driven by equity raises reflected in stockholders' equity growth to $3.3B.
• ·Redeemable convertible preferred stock redeemed in full ($1.1B liquidation preference).
• ·Cash and cash equivalents segregated for stablecoin holders grew 70.9% to $75.1B.

09-03-2026

Enterprise Financial Services Corp announced on March 9, 2026, the availability of an investor presentation for use by management in meetings with investors, analysts, and other interested parties. The materials are filed as Exhibit 99.1 to this Form 8-K. No specific financial metrics or performance data were disclosed in the filing itself.

• ·Securities registered: Common Stock (EFSC) and Depositary Shares (EFSCP) on Nasdaq Global Select Market
• ·Principal executive offices: 150 N. Meramec Avenue, St. Louis, Missouri 63105

09-03-2026

Pulse Biosciences, Inc. announced long-term follow-up data from its nPulse™ Vybrance™ Percutaneous Electrode System first-in-human feasibility study for benign thyroid nodule ablation, presented on March 6, 2026, at the North American Society for Interventional Thyroidology meeting. Key results from 21 patients monitored 15-22 months post-treatment include an average 74% nodule volume reduction with continued improvements over time, no regrowth, no serious adverse events, 100% patient cosmetic satisfaction, and 95% overall satisfaction. No negative outcomes or flat metrics were reported.

• ·No regrowth of nodules at 15-22 months
• ·No serious adverse events
• ·No intranodular fibrosis detected on ultrasounds at 15-22 months
• ·Data presented by Professor Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting in Portland, Oregon

09-03-2026

Citizens Financial Group, Inc. (CFG) filed Definitive Additional Proxy Materials (DEFA14A) on March 09, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing covers the fiscal year from January 1, 2025, to December 31, 2025, and indicates no filing fee was required. No specific proposals, financial data, or shareholder actions are detailed in the provided content.

09-03-2026

HPE reported fiscal 2026 Q1 revenue of $9.3B, up 18% YoY, propelled by Networking revenue surging 151.5% to $2.7B amid strong demand across sub-segments like Data Center Networking (+382.6%). However, Cloud & AI revenue fell 2.7% YoY to $6.3B, with Server down 2.7%, Storage up 0.6%, and Financial Services up 0.3%; Corporate Investments and Other declined 2.2%. Non-GAAP gross margins improved to 36.6% (up 720 bps YoY), non-GAAP EPS rose to $0.65 (up $0.16), and the company raised FY26 outlook including 17-22% revenue growth and $2.30-$2.50 non-GAAP EPS.

• ·GAAP diluted EPS $0.31, down $0.13 YoY but above outlook ($0.09-$0.13).
• ·Non-GAAP diluted EPS $0.65, up $0.16 YoY and above outlook ($0.57-$0.61).
• ·Regular cash dividend of $0.1425 per share, record date March 24, 2026, payable April 23, 2026.
• ·Q2 FY26 outlook: revenue $9.6B-$10.0B; non-GAAP EPS $0.51-$0.55.
• ·FY26 full year outlook: revenue growth 17-22%; Networking growth 68-73%; non-GAAP EPS $2.30-$2.50; FCF at least $2.0B.

09-03-2026

Financial Institutions Inc reported a strong profitability recovery in 2025 with net income available to common shareholders of $73.4M, up significantly from a $43.1M loss in 2024 and 50% above $48.8M in 2023, driving ROAE to 12.49% and ROAA to 1.20%. Net interest margin expanded to 3.53% from 2.86% YoY amid higher loan rates, efficiency ratio improved sharply to 58.13% from 82.35%, and capital ratios strengthened with CET1 at 11.11%. However, noninterest income fell to $45.0M from $48.2M in 2023 due to lower insurance and card income, average consumer indirect loans declined to $837M from $895M and $998M, and total assets grew modestly 3% YoY to $6.27B.

• ·Nonaccrual loans declined to $35.1M at Dec 31, 2025 from $41.4M in 2024.
• ·Interest expense decreased 11% YoY to $133.0M in 2025 from $149.6M.
• ·Provision for litigation settlement was $0 in 2025 vs $23.0M in 2024.
• ·Net gain on investment securities of $0.9M in 2025 vs $100.1M loss in 2024.

09-03-2026

Western Asset Municipal High Income Fund Inc. (MHF) issued a proxy statement for its Annual Meeting of Stockholders on April 17, 2026, at 10:00 a.m. New York time, to elect three Class III Directors (Proposal 1) and ratify PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending October 31, 2026 (Proposal 2). The record date is February 6, 2026, with 22,206,849 shares of common stock outstanding. No financial performance data, period comparisons, or other metrics are provided in the filing.

• ·Meeting location: One Madison Avenue, 17th Floor, New York, New York 10010
• ·Fund's investment adviser: Franklin Templeton Fund Adviser, LLC (FTFA); subadviser: Western Asset Management Company, LLC
• ·Fund organized as Maryland corporation and registered investment company
• ·Quorum requires majority of outstanding shares; abstentions and broker non-votes count for quorum but not votes

09-03-2026

Daré Bioscience, Inc. completed the second closing of its Regulation A offering on March 6, 2026, issuing 17,500 Investor Units at $5.00 each, for gross proceeds of $87,500, consisting of 17,500 shares of Series A Convertible Preferred Stock and warrants to purchase up to 35,000 shares of common stock. The total offering is for up to 4,854,000 Investor Units. The offering was qualified by the SEC on January 5, 2026.

• ·Offering statement qualified by SEC on January 5, 2026; offering circular dated January 6, 2026
• ·Registrant details: Delaware incorporation, Commission File Number 001-36395, EIN 20-4139823, address 3655 Nobel Drive, Suite 260, San Diego, CA 92122

09-03-2026

CIMG Inc. filed an 8-K on 2026-03-09 under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No financial metrics, transaction values, or additional details such as reasons for delisting, dollar impacts, or balance sheet effects were disclosed. This represents a material negative event with no offsetting positive information provided.

• ·Filing Accession Number: 0001493152-26-009365
• ·File size: 205 KB
• ·Event type: Delisting
• ·Sector: NOT_DISCLOSED